Joshua Lugo

Joshua Lugo

Auto-generated profile, based on publicly available information

Joshua Lugo

Department of Physiology and Neuroscience and Zilkha Neurogenetic Institute, Keck School of Medicine, University of Southern California, Los Angeles, California, USA

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 December 2025 in Journal of Biological Chemistry
Verified
Journal Article
Open access
JLJoshua Lugo
Joshua Lugo
HXHui Xu
Hui Xu
JCJeannie Chen
Jeannie Chen
AKAli Khoshnan
Ali Khoshnan
RLRalf Langen
Ralf Langen
Misfolding and aggregation of huntingtin exon-1 (Httex1) with an expanded polyglutamine region is a key pathological hallmark of Huntington's disease, making conformationally specific Httex1 binders potentially valuable diagnostic or therapeutic tools. To define epitopes, which might confer conformationally specific Httex1 binding, we characterized five newly developed huntingtin antibodies (PHP5-PHP9). Binding to recombinant proteins as well as staining of human embryonic kidney 293 cells and R6/1 mice shows that PHP5 and PHP6 preferentially bind monomers over fibrils. Using electron paramagnetic resonance, peptide arrays, and deletion mutants, we mapped binding of PHP5 and PHP6 to the hydrophobic surface of an N-terminal α-helix spanning residues 4 to 18 of Httex1. In contrast, PHP7, PHP8, and PHP9, raised against protofibrils, recognize proline repeats within the C-terminal proline-rich domain (PRD). These antibodies showed a preference for aggregates in cells, but neither the N-terminal N17 region nor the polyglutamine fibril-forming core region was required. Similar fibril binding was also observed with an α-synuclein-PRD chimera, where the PRD was fused to the fibril-forming core of α-synuclein. Thus, a high density of PRD regions, rather than fibril core features, is needed for fibril binding. Interestingly, all PRD-binding antibodies, including PHP1 and P90, preferentially bound aggregates, but recognition of different cellular aggregates varied, revealing heterogeneity both within aggregates (rim versus interior) and between aggregates. Together, the binding principles uncovered here could serve as a basis for the design and optimization of binders with potential diagnostic or therapeutic relevance.

21 October 2025 in bioRxiv
Verified
Preprint
Open access
KNKaori Noridomi
Kaori Noridomi
JIJ. Mario Isas
J. Mario Isas
AAAnakha Ajayan
Anakha Ajayan
TMTristan McPhail
Tristan McPhail
HXHui Xu
Hui Xu
RRRichard W. Roberts
Richard W. Roberts
In Huntingtons disease, polyglutamine expansion in huntingtin exon 1 (Httex1) results in stepwise misfolding, amyloid formation, and neuronal death. Here we used mRNA display directed evolution to generate peptide ligands targeting Httex1 protofibrils, an early, toxic misfolding intermediate. Two distinct peptide families bind protofibrils, one tryptophan rich and the other glutamine rich, resulting in two predominant peptides HD1 (W-rich) and HD8 (Q-rich). Both peptides bind with high affinity and specificity to the misfolded polyQ structure present in protofibrils, a toxic component that is not recognized by existing huntingtin-directed antibodies. Homo- and heterodimers of HD1 and HD8 bind protofibrils with antibody-like affinity, and potently inhibit aggregation of recombinant and cellular Httex1. The HD8-1 heterodimer can be used like an antibody for immunocytochemistry to identify Httex1 aggregates in transfected cells and in the retina of a Huntingtons disease mouse model system (R6/1). Peptide binding to both in vitro and in vivo Httex1 validates in vitro generated Httex1 protofibrils share the same structural features as Httex1 amyloid from cellular and mammalian disease model systems. Further, HD8-1 protofibril recognition enables direct detection of a pathogenic form of Httex1 (misfolded polyQ) as a disease biomarker. Finally, HD1, HD8, and HD8-1 binding and aggregation inhibition defines the protofibril sites that mediate fibril growth. Overall, our observations support developing protofibril-directed ligands as novel, selective, diagnostics and therapeutics for Huntingtons disease. Significance Statement: Huntingtin protein polyQ misfolding plays a central role in Huntington’s disease pathogenesis. We used mRNA display to discover a new class of huntingtin-directed ligands protofibril-binding peptides. Unlike presently available antibodies, these peptides selectively recognize misfolded polyQ region, enable using toxic huntingtin aggregates as disease biomarkers, and block huntingtin aggregation in vitro and in vivo . Protofibril binding peptides may thus assist analysis of huntingtin pathology and provide a starting point for designing protein misfolding inhibitors as Huntington’s disease therapeutics.